Medication-Related Osteonecrosis of the Jaw: Basic and Translational Science Updates.
In the late 1990s and the early 2000s, bisphosphonates had become the clinical pillar of excellence for treating metabolic bone disease, and thus their connection with osteonecrosis of the jaw (ONJ) caused significant concern. Over the past decade, progress has been made in understanding what is now referred to as medication-related ONJ (MRONJ), because of its connections to agents other than bisphosphonates, although in many respects the progress has been slow. This review highlights the key basic science and translational (animal) studies in the area of MRONJ and suggests areas of focus as the field moves into the next decade.
Department of Anatomy and Cell Biology, Indiana University School of Medicine, 635 Barnhill Drive, MS-5035, Indianapolis, IN 46202, USA. Electronic address: matallen@iupui.edu.
Matthew R
MR
Allen
D020533:Angiogenesis Inhibitors / Q000633:toxicity*; D000818:Animals; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000473:pathology; D050071:Bone Density Conservation Agents / Q000633:toxicity*; D004164:Diphosphonates / Q000633:toxicity*; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced* / Q000473:pathology; D010020:Osteonecrosis / Q000139:chemically induced* / Q000473:pathology; D057170:Translational Research, Biomedical
D020533:Angiogenesis Inhibitors; D050071:Bone Density Conservation Agents; D004164:Diphosphonates
Antiremodeling agents; Bisphosphonates; Denosumab; ONJ